Discover and read the best of Twitter Threads about #AACR19
Most recents (1)
Missed the talk? Here's a summary of latest data on the selective next-gen TRK inhibitor LOXO-195 (BAY 2731954). On-target resistance to current inhibitors driven by kinase mutations in 3 positions (SF, xDFG, GK) - SF likely most common. #AACR19 @sloan_kettering @AACR 1/x 
LOXO-195 evaluated in 2 programs: formal Phase 1 dose escalation and @FDAOncology #ExpandedAccess program 👏 (for pts unable to enroll in P1). Here's the key eligibility and combined patient demographics. 15 tumor types. 30 pts TRKi resistant, 1 intolerant. 2/x
Patients were enrolled regardless of specific TRKi resistance mechanism - so it was important to retrospectively define. This was done by: 1) local tissue sequencing and/or 2) central cfDNA - summary below. 3/x
